Inflation data this week has come in below forecasts. Earnings season is off to a solid start. Is this the medicine the ...
J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.
Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...
Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
Zacks.com on MSN1h
LLY Stock Down on Lower-Than-Expected Sales Guidance for Q4Eli Lilly and Company’s LLY shares declined 6.6% on Tuesday after the company lowered its sales guidance for full-year 2024 ...
Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...
The Paris-based organization now forecasts global demand to grow by 1.05 million barrels a day in 2025 from 1.1 million barrels a day previously, reaching a total of 104 million barrels a day on ...
Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at ...
World stocks are mixed follow Wall Street’s mostly positive performance ahead of key U.S. inflation data that could influence ...
Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter ...
The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback